What does the study involve?

When you join this study, you will have an initial telephone interview with a representative from the registry study that will last about 45 minutes. They will make sure to explain everything clearly and answer any questions you may have. You will also need to consent to your doctor sharing information about the health of you and your child. Some information may be collected from past medical records. If needed, follow-up telephone interviews will last about 10–15 minutes. You and your infant will not be expected to take medications or make any study visits.

How long will my participation in the study last?

Your involvement with this study will last for the duration of your pregnancy or until your baby is 1 year old.

What else do I need to know?

- This study has been reviewed by an Institutional Review Board (IRB)/Ethics Committee (EC). An IRB/EC protects the rights, safety, and well-being of study participants.
- If you decide you want to enroll in the registry, we will send you a welcome message by email.
- If you change your mind about the study, you may leave at any time.

Interested in taking part?

Please visit **www.UltomirisPregnancyStudy.com** to learn more and see if the study might be a good fit for you.

By sharing your experience, you could help other women and their doctors to better understand if ULTOMIRIS has any effect on pregnancy, delivery, or the health of babies.

Patient Brochure, 17 Jun 2024 [V01 USA(en)]

Ultomiris Pregnancy Registry Study

Patient Information

ALEXION®
AstraZeneca Rare Disease

About the Ultomiris Pregnancy Registry Study

Thank you for considering this important study. This study will help to understand important facts about the effects of ULTOMIRIS® (ravulizumab) on women and their babies during pregnancy, delivery, and breastfeeding. You may discuss this Brochure with your doctor if you have any questions about the study.

What is a pregnancy registry study?

Pregnancy registries are observational studies created to help healthcare providers (HCPs) learn more about medications and their effects on women and their babies. This is because pregnant women are often not allowed to participate in studies that research potential new medications.

There are no tests or additional medications required as part of an observational study. All information collected in this study is shared by you or your HCP during phone calls with the study team or from past medical records.

The Ultomiris Pregnancy Registry Study will look at a prescription medication used to treat rare autoimmune conditions called ULTOMIRIS. Although ULTOMIRIS is an approved medication (which means doctors can prescribe it for patients to use), there is not a lot of information on how ULTOMIRIS might affect pregnancies or the health of babies.

Who can take part?

The Ultomiris Pregnancy Registry Study is looking for volunteers who:

- are pregnant or have been pregnant AND
- have paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), or neuromyelitis optica spectrum disorder (NMOSD) AND
- received ULTOMIRIS up to about 9 months before pregnancy, during pregnancy, or while breastfeeding.

Up to **75** participants